These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35245971)

  • 1. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy.
    Ersoy M; Pişkinpaşa H
    J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac involvement in Lysosomal Storage Diseases.
    Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 8. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease.
    Crivaro AN; Mucci JM; Bondar CM; Ormazabal ME; Ceci R; Simonaro C; Rozenfeld PA
    PLoS One; 2019; 14(5):e0217780. PubMed ID: 31150494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality of life of 22 patients with type 1 Gaucher disease after enzyme replacement therapy].
    Li HM; Zhang RX; Long ZB; Du YL; Chen M; Zhuang JL; Qiu ZQ; Han B
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):287-291. PubMed ID: 32447931
    [No Abstract]   [Full Text] [Related]  

  • 12. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
    Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
    Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1.
    Alioto AG; Gomez R; Moses J; Paternostro J; Packman S; Packman W
    Am J Med Genet A; 2020 May; 182(5):1130-1142. PubMed ID: 32125090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What should rheumatologists know about Gaucher disease and Fabry disease? Connecting the dots for an overview.
    Cordeiro RA; Rosa Neto NS; Giardini HAM
    Adv Rheumatol; 2024 Mar; 64(1):22. PubMed ID: 38520029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
    Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
    Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of postpartum hemorrhage in multiparous women with Gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients.
    Cohen Y; Frydman D; Rotem R; Kofman R; Zimran A; Revel-Vilk S; Grisaru-Granovsky S
    J Inherit Metab Dis; 2021 Sep; 44(5):1165-1173. PubMed ID: 33829536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
    Stein P; Malhotra A; Haims A; Pastores GM; Mistry PK
    J Inherit Metab Dis; 2010 Dec; 33(6):769-74. PubMed ID: 20683668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.